Surrozen, Inc./DE Diluted Shares Outstanding (Weighted Average)
Surrozen, Inc./DE (SRZN) reported Diluted Shares Outstanding (Weighted Average) of 23.15 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- Surrozen, Inc./DE weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 23.15M shares, a 171.00% increase year-over-year.
- Surrozen, Inc./DE weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 10.95K shares, a 201.79% increase year-over-year.
- Surrozen, Inc./DE weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 9.12K shares, a 180.24% increase year-over-year.
- Surrozen, Inc./DE weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 8.57K shares, a 165.52% increase year-over-year.
- Surrozen, Inc./DE weighted average number of shares outstanding, diluted for fiscal 2025 was 7.48K shares, a 154.96% increase from fiscal 2024.
- Surrozen, Inc./DE weighted average number of shares outstanding, diluted for fiscal 2024 was 2.93K shares, a 45.34% increase from fiscal 2023.
- Surrozen, Inc./DE weighted average number of shares outstanding, diluted for fiscal 2023 was 2.02K shares, a 12.79% decline from fiscal 2022.
- Surrozen, Inc./DE weighted average number of shares outstanding, diluted for fiscal 2022 was 2.31K shares, a 90.63% decline from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month | Weighted Average Number of Shares Outstanding, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 23.15M shares 10-Q · filed 2026-08-06 | 11.31M shares 10-Q · filed 2026-08-06 | 7.72M shares derived: average of 3 quarters · filed 2026-08-06 | 5.79M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | 10.95K shares 10-Q · filed 2026-05-06 | 10.03K shares derived: average of 2 quarters · filed 2026-05-06 | 9.55K shares derived: average of 3 quarters · filed 2026-05-06 | 2.14M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | 9.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 8.85K shares derived: average of 2 quarters · filed 2026-03-23 | 2.85M shares derived: average of 3 quarters · filed 2026-08-06 | 7.48K shares 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | 8.57K shares 10-Q · filed 2025-11-07 | 4.27M shares derived: average of 2 quarters · filed 2026-08-06 | 6.93K shares 10-Q · filed 2025-11-07 | 2.14M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | 8.54M shares 10-Q · filed 2026-08-06 | 8.54K shares 10-Q · filed 2025-08-08 | 6.10M shares 10-Q · filed 2026-08-06 | 6.10K shares 10-Q · filed 2025-08-08 | 2.85M shares derived: average of 3 quarters · filed 2026-08-06 | 2.14M shares derived: average of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | 3.63K shares 10-Q · filed 2026-05-06 | 3.44K shares derived: average of 2 quarters · filed 2026-05-06 | 3.37K shares derived: average of 3 quarters · filed 2026-05-06 | 3.32K shares derived: average of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | 3.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 3.24K shares derived: average of 2 quarters · filed 2026-03-23 | 3.21K shares derived: average of 3 quarters · filed 2026-03-23 | 2.93K shares 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | 3.23K shares 10-Q · filed 2025-11-07 | 3.23M shares 10-Q · filed 2024-11-06 | 3.19K shares derived: average of 2 quarters · filed 2025-11-07 | 2.83K shares 10-Q · filed 2025-11-07 | 2.83M shares 10-Q · filed 2024-11-06 | -1.50M shares derived: average of 4 quarters · filed 2025-11-07 | ||
| 2024-06-30 | 3.16K shares 10-Q · filed 2025-08-08 | 3.16M shares 10-Q · filed 2024-08-12 | 2.62K shares 10-Q · filed 2025-08-08 | 2.62M shares 10-Q · filed 2024-08-12 | -2.01M shares derived: average of 3 quarters · filed 2025-08-08 | -997.42K shares derived: average of 4 quarters · filed 2025-08-08 | ||
| 2024-03-31 | 2.08K shares 10-Q · filed 2025-05-09 | -3.01M shares derived: average of 2 quarters · filed 2025-05-09 | -1.33M shares derived: average of 3 quarters · filed 2025-05-09 | -497.21K shares derived: average of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | -6.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -2.00M shares derived: average of 2 quarters · filed 2025-03-31 | -663.64K shares derived: average of 3 quarters · filed 2025-03-31 | 2.02K shares 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | 2.03M shares 10-Q · filed 2024-11-06 | 30.50M shares 10-Q · filed 2023-11-08 | 2.02M shares derived: average of 2 quarters · filed 2024-11-06 | 2.01M shares 10-Q · filed 2024-11-06 | 30.18M shares 10-Q · filed 2023-11-08 | -25.18M shares derived: average of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | 2.00M shares 10-Q · filed 2024-08-12 | 30.07M shares 10-Q · filed 2023-08-09 | 2.00M shares 10-Q · filed 2024-08-12 | 30.02M shares 10-Q · filed 2023-08-09 | -34.25M shares derived: average of 3 quarters · filed 2024-08-12 | -16.95M shares derived: average of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | 2.00K shares 10-Q · filed 2024-05-08 | 29.97K shares 10-Q · filed 2023-05-10 | -52.38M shares derived: average of 2 quarters · filed 2024-05-08 | -23.27M shares derived: average of 3 quarters · filed 2024-05-08 | -8.71M shares derived: average of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | -104.77M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | -34.90M shares derived: average of 2 quarters · filed 2024-04-10 | -11.62M shares derived: average of 3 quarters · filed 2024-04-10 | 2.31K shares 10-K · filed 2024-04-10 | 34.72K shares 10-K · filed 2023-03-31 | |||
| 2022-09-30 | 34.97M shares 10-Q · filed 2023-11-08 | 34.97K shares 10-Q · filed 2022-11-14 | 34.96M shares derived: average of 2 quarters · filed 2023-11-08 | 34.93M shares 10-Q · filed 2023-11-08 | 34.93K shares 10-Q · filed 2022-11-14 | 10.25M shares derived: average of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | 34.95M shares 10-Q · filed 2023-08-09 | 34.95K shares 10-Q · filed 2022-08-11 | 34.90M shares 10-Q · filed 2023-08-09 | 34.90K shares 10-Q · filed 2022-08-11 | 2.01M shares derived: average of 3 quarters · filed 2023-08-09 | 8.36M shares derived: average of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | 34.86M shares 10-Q · filed 2023-05-10 | -14.46M shares derived: average of 2 quarters · filed 2023-05-10 | -503.08K shares derived: average of 3 quarters · filed 2023-05-10 | 4.18M shares derived: average of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -63.77M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -18.19M shares derived: average of 2 quarters · filed 2023-03-31 | -6.05M shares derived: average of 3 quarters · filed 2023-03-31 | 24.69K shares 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | 27.40M shares 10-Q · filed 2022-11-14 | 22.81M shares derived: average of 2 quarters · filed 2022-11-14 | 21.29M shares 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 18.22M shares 10-Q · filed 2022-08-11 | 18.19M shares 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |